Plus: Comcast rolls out small-business assistance; Richie Neal takes Trump to task for tariff policies; Healey rolls out new ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p14,200.00. The ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £110.00. The company’s shares opened today at p10,500. ...

Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, seeking to accelerate the development of its cell therapy capabilities, ...

In Q4 2024, AstraZeneca PLC (NASDAQ:AZN) was included in 14 billionaire portfolios with a total of $2.20 billion in combined ...

AstraZeneca PLC closed 22.92% short of its 52-week high of £133.88, which the company reached on September 3rd.

The EU approved AstraZeneca’s Imfinzi for limited-stage small cell lung cancer, reducing the risk of death by 27% in ADRIATIC Phase 3 trial. With stocks plunging, steady income is key.

AstraZeneca PLC closed 27.79% below its 52-week high of £133.88, which the company achieved on September 3rd.

AstraZeneca PLC (LSE/STO/Nasdaq ... by the European Union for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...